세계의 흡입 일산화질소 시장 : 용도별-기회 분석 및 산업 예측(2023-2032년)

The global inhaled nitric oxide market was valued at $0.8 billion in 2022, and is projected to reach $1.6 billion by 2032, growing at a CAGR of 7.7% from 2023 to 2032

Inhaled nitric oxide is a therapeutic gas used to manage and treat hypoxic respiratory failure or persistent pulmonary hypertension in newborns. Inhaled nitric oxide is a selective pulmonary vasodilator, meaning it helps improve blood flow to well-ventilated areas of the lung, thus improving ventilation-perfusion matching and reducing pulmonary hypertension. The primary mechanism of action involves the activation of guanylate cyclase in smooth muscle cells, leading to an increase in cyclic guanosine monophosphate (cGMP) and subsequent vasodilation.

The growth of the inhaled nitric oxide market is attributed to the high adoption of the inhaled nitric oxide for neonatal hypoxic respiratory failure and rise in prevalence of chronic obstructive pulmonary disease. The high adoption of inhaled nitric oxide for neonatal hypoxic respiratory failure stands out as a major driver propelling the growth of the inhaled nitric oxide market. In recent years, inhaled nitric oxide has emerged as a crucial therapeutic intervention in the neonatal care landscape, particularly for infants experiencing respiratory distress due to hypoxic conditions. For instance, the U.S. Food and Drug Administration has approved INOmax in 1999 and Genosyl in 2019 for term and near-term infants (>34 weeks' gestation) with hypoxic respiratory failure associated with clinical or echocardiographic signs of pulmonary hypertension to improve oxygenation and lower the risk of extracorporeal membrane oxygenation.

Neonates often face challenges in adapting to extrauterine life, and hypoxic respiratory failure is a critical concern during this transitional period. Inhaled nitric oxide, with its vasodilatory properties, acts selectively on the pulmonary vasculature, improving oxygenation by dilating the pulmonary vessels and reducing pulmonary hypertension. Its efficacy in enhancing oxygen delivery while minimizing potential systemic side effects has garnered widespread acceptance among healthcare professionals.

The increased prevalence of neonatal hypoxic respiratory failure, attributed to factors such as premature birth and congenital disorders, has led to a surge in the demand for effective treatment options, further driving the adoption of inhaled nitric oxide. Moreover, the growth in awareness among healthcare providers about the benefits of inhaled nitric oxide in preventing or mitigating hypoxic-induced complications has contributed to widespread incorporation of inhaled nitric oxide into neonatal intensive care protocols. Thus, the high adoption of the inhaled nitric oxide for neonatal hypoxic respiratory failure is expected to drive the growth of the inhaled nitric oxide.

Furthermore, rise in prevalence of chronic obstructive pulmonary disease is expected to drive the growth of the market. Chronic obstructive pulmonary disease, a progressive and debilitating respiratory condition primarily caused by prolonged exposure to harmful particles or gases, such as those found in cigarette smoke, is reaching alarming levels globally. For instance, according to the 2022 report by the National Library of Medicine, it was reported that chronic obstructive pulmonary disease (COPD) has a worldwide prevalence of 10.1% in people aged 40 years or older. As the incidence of COPD continues to rise, there is an urgent demand for effective therapeutic interventions that can alleviate the symptoms and enhance the overall quality of life for affected individuals. The adoption of inhaled nitric oxide has surged owing to its potential in managing respiratory disorders, including COPD. The vasodilatory and anti-inflammatory properties of nitric oxide make it a promising candidate for improving pulmonary function. Thus, the rise in the prevalence of chronic obstructive pulmonary disease is expected to contribute significantly to the growth of the market.

The inhaled nitric oxide market is segmented on the basis of application, and region. By application, the market is classified into neonatal respiratory treatment, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, and rest of Europe), Asia-Pacific (Japan, Australia, and rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa).

Major key players that operate in the global inhaled nitric oxide market are Air Liquide S.A, Linde Plc, Mallinckrodt Plc, Vero Biotech LLC, Chemix Specialty Gases and Equipment, Air Water Inc, Sichuan Salman Chemical Products Co., Ltd, Linde PLC, SOL Group, Nippon Sanso Holdings Corporation and Chengdu Taiyu Industrial Gases Co., Ltd.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the inhaled nitric oxide market analysis from 2022 to 2032 to identify the prevailing inhaled nitric oxide market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the inhaled nitric oxide market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global inhaled nitric oxide market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Patient/epidemiology data at country, region, global level
• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• SWOT Analysis

Key Market Segments

By Application

• Neonatal Respiratory Treatment
• Chronic Obstructive Pulmonary Disease
• Acute Respiratory Distress Syndrome
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia-Pacific
  • Japan
  • Australia
  • Rest of Asia-Pacific
• LAMEA
  • Latin America
  • Middle East And Africa

Key Market Players:

• Air Liquide S.A.
• Mallinckrodt plc
• Chemix Specialty Gases and Equipment
• Vero Biotech LLC
• Air Water Inc.
• Sichuan Salman Chemical Products Co., Ltd
• Linde PLC
• SOL Group
• Nippon Sanso Holdings Corporation
• Chengdu Taiyu Industrial Gases Co., Ltd.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Moderate bargaining power of suppliers
  • 3.3.2. Moderate threat of new entrants
  • 3.3.3. Moderate threat of substitutes
  • 3.3.4. Moderate intensity of rivalry
  • 3.3.5. Moderate bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. High adoption of the inhaled nitric oxide for management of pulmonary disorders in the infants and newborns.
    • 3.4.1.2. Rise in prevalence of the respiratory disorders.
    • 3.4.1.3. Advancements in healthcare infrastructure.
  • 3.4.2. Restraints
    • 3.4.2.1. High cost of inhaled nitric oxide.
  • 3.4.3. Opportunities
    • 3.4.3.1. High research and development activities for inhaled nitric oxide.
• 3.5. Market Share Analysis

CHAPTER 4: INHALED NITRIC OXIDE MARKET, BY APPLICATION

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Neonatal Respiratory Treatment
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Chronic Obstructive Pulmonary Disease
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Acute Respiratory Distress Syndrome
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
• 4.5. Others
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country

CHAPTER 5: INHALED NITRIC OXIDE MARKET, BY REGION

• 5.1. Overview
  • 5.1.1. Market size and forecast By Region
• 5.2. North America
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by Application
  • 5.2.3. Market size and forecast, by country
    • 5.2.3.1. U.S.
    • 5.2.3.1.1. Market size and forecast, by Application
    • 5.2.3.2. Canada
    • 5.2.3.2.1. Market size and forecast, by Application
    • 5.2.3.3. Mexico
    • 5.2.3.3.1. Market size and forecast, by Application
• 5.3. Europe
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by Application
  • 5.3.3. Market size and forecast, by country
    • 5.3.3.1. Germany
    • 5.3.3.1.1. Market size and forecast, by Application
    • 5.3.3.2. France
    • 5.3.3.2.1. Market size and forecast, by Application
    • 5.3.3.3. UK
    • 5.3.3.3.1. Market size and forecast, by Application
    • 5.3.3.4. Italy
    • 5.3.3.4.1. Market size and forecast, by Application
    • 5.3.3.5. Rest of Europe
    • 5.3.3.5.1. Market size and forecast, by Application
• 5.4. Asia-Pacific
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by Application
  • 5.4.3. Market size and forecast, by country
    • 5.4.3.1. Japan
    • 5.4.3.1.1. Market size and forecast, by Application
    • 5.4.3.2. Australia
    • 5.4.3.2.1. Market size and forecast, by Application
    • 5.4.3.3. Rest of Asia-Pacific
    • 5.4.3.3.1. Market size and forecast, by Application
• 5.5. LAMEA
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by Application
  • 5.5.3. Market size and forecast, by country
    • 5.5.3.1. Latin America
    • 5.5.3.1.1. Market size and forecast, by Application
    • 5.5.3.2. Middle East And Africa
    • 5.5.3.2.1. Market size and forecast, by Application

CHAPTER 6: COMPETITIVE LANDSCAPE

• 6.1. Introduction
• 6.2. Top winning strategies
• 6.3. Product mapping of top 10 player
• 6.4. Competitive dashboard
• 6.5. Competitive heatmap
• 6.6. Top player positioning, 2022

CHAPTER 7: COMPANY PROFILES

• 7.1. Air Liquide S.A.
  • 7.1.1. Company overview
  • 7.1.2. Key executives
  • 7.1.3. Company snapshot
  • 7.1.4. Operating business segments
  • 7.1.5. Product portfolio
  • 7.1.6. Business performance
• 7.2. Linde PLC
  • 7.2.1. Company overview
  • 7.2.2. Key executives
  • 7.2.3. Company snapshot
  • 7.2.4. Operating business segments
  • 7.2.5. Product portfolio
  • 7.2.6. Business performance
  • 7.2.7. Key strategic moves and developments
• 7.3. Mallinckrodt plc
  • 7.3.1. Company overview
  • 7.3.2. Key executives
  • 7.3.3. Company snapshot
  • 7.3.4. Operating business segments
  • 7.3.5. Product portfolio
  • 7.3.6. Business performance
• 7.4. Vero Biotech LLC
  • 7.4.1. Company overview
  • 7.4.2. Key executives
  • 7.4.3. Company snapshot
  • 7.4.4. Operating business segments
  • 7.4.5. Product portfolio
• 7.5. SOL Group
  • 7.5.1. Company overview
  • 7.5.2. Key executives
  • 7.5.3. Company snapshot
  • 7.5.4. Operating business segments
  • 7.5.5. Product portfolio
  • 7.5.6. Business performance
  • 7.5.7. Key strategic moves and developments
• 7.6. Air Water Inc.
  • 7.6.1. Company overview
  • 7.6.2. Key executives
  • 7.6.3. Company snapshot
  • 7.6.4. Operating business segments
  • 7.6.5. Product portfolio
  • 7.6.6. Business performance
• 7.7. Chemix Specialty Gases and Equipment
  • 7.7.1. Company overview
  • 7.7.2. Key executives
  • 7.7.3. Company snapshot
  • 7.7.4. Operating business segments
  • 7.7.5. Product portfolio
• 7.8. Nippon Sanso Holdings Corporation
  • 7.8.1. Company overview
  • 7.8.2. Key executives
  • 7.8.3. Company snapshot
  • 7.8.4. Operating business segments
  • 7.8.5. Product portfolio
  • 7.8.6. Business performance
• 7.9. Chengdu Taiyu Industrial Gases Co., Ltd.
  • 7.9.1. Company overview
  • 7.9.2. Key executives
  • 7.9.3. Company snapshot
  • 7.9.4. Operating business segments
  • 7.9.5. Product portfolio
• 7.10. Sichuan Salman Chemical Products Co., Ltd
  • 7.10.1. Company overview
  • 7.10.2. Key executives
  • 7.10.3. Company snapshot
  • 7.10.4. Operating business segments
  • 7.10.5. Product portfolio